1,4:3,6-二脱水-2-脱氧-2-{[2-羟基-3-(3-甲基苯氧基)丙基]氨基}-5-O-硝基-L-艾杜糖醇盐酸 | 27321-31-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1,4:3,6-二脱水-2-脱氧-2-{[2-羟基-3-(3-甲基苯氧基)丙基]氨基}-5-O-硝基-L-艾杜糖醇盐酸
• 中文别名: 2-异丙基-5-甲基-1H-吲哚
• 英文名称: 2-Isopropyl-5-methylindol
• 英文别名: 2-isopropyl-5-methyl-indole；2-Isopropyl-5-methyl-1H-indole；5-methyl-2-propan-2-yl-1H-indole
• CAS: 27321-31-9
• 化学式: C₁₂H₁₅N
• 分子量: 173.258
• InChiKey: NGSXHQNEQTUVDH-UHFFFAOYSA-N

物化性质

• 沸点：
  299.2±9.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  15.8
• 氢给体数：
  1
• 氢受体数：
  0

文献信息

• [EN] STAT DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE STAT ET LEURS UTILISATIONS
  申请人：KYMERA THERAPEUTICS INC

  公开号：WO2021188696A1

  公开（公告）日：2021-09-23

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• [EN] SMALL MOLECULE STAT PROTEIN DEGRADERS<br/>[FR] AGENTS DE DÉGRADATION DE PROTÉINE STAT À PETITES MOLÉCULES
  申请人：UNIV MICHIGAN REGENTS

  公开号：WO2021195481A1

  公开（公告）日：2021-09-30

  The present disclosure provides compounds represented by Formula (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R3a, R4, A, E1, E2, M, and Q are as set forth in the specification. Compounds of Formula (I) are STAT protein degraders and thus are useful for the treatment of cancer and other diseases.

  本公开提供由式（I）表示的化合物及其药用可接受的盐和溶剂化物，其中R1a、R1b、R3a、R4、A、E1、E2、M和Q如规范中所述。式（I）的化合物是STAT蛋白降解物，因此对于癌症和其他疾病的治疗是有用的。
• Spirocycle compounds and methods of making and using same
  申请人：H. Lundbeck A/S

  公开号：US11142526B2

  公开（公告）日：2021-10-12

  Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.

  本文提供了可用作 MAGL 调节剂的化合物和组合物。此外，这些化合物和组合物还可用于治疗疼痛。
• HEPATITIS C VIRUS INHIBITORS
  申请人：Or Yat Sun

  公开号：US20110008288A1

  公开（公告）日：2011-01-13

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• QUINOLONE COMPOUND
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20150005287A2

  公开（公告）日：2015-01-01

  The present invention provides a compound represented by the formula (I) wherein X is a hydrogen atom or a fluorine atom; R is a hydrogen atom or alkyl; R 1 is (1) cyclopropyl optionally substituted by to 3 halogen atoms or (2) phenyl optionally substituted by 1 to 3 halogen atoms; R 2 is alkyl, alkoxy, haloalkoxy, a halogen atom, cyano, etc.; and R 3 is 7-oxo-7,8-dihydro-1,8-naphthyridinyl, 3-pyridyl, etc., or a salt thereof. The compound of the present invention has excellent antimicrobial activity against Clostridium difficile and is useful for the prevention or treatment of intestinal infection such as Clostridium difficile -associated diarrhea.